{"id":250,"date":"2026-04-11T10:25:54","date_gmt":"2026-04-11T10:25:54","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=250"},"modified":"2026-08-30T03:53:23","modified_gmt":"2026-08-30T03:53:23","slug":"lucifine-10-mgx30-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/es\/product\/lucifine-10-mgx30-tablets\/","title":{"rendered":"LUCIFINE"},"content":{"rendered":"<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>These highlights do not include all the information needed to use LUCIFINE safely and effectively. See full prescribing information for LUCIFINE.<\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>INDICATIONS AND USAGE<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">LUCIFINE is a non-steroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DOSAGE AND ADMINISTRATION<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;The recommended starting dosage is 10 mg or 20 mg orally once daily based on estimated glomerular filtration rate (eGFR) and serum potassium thresholds.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Increase dosage after 4 weeks to the target dose of 20 mg once daily, based on eGFR and serum potassium thresholds.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Tablets may be taken with or without food.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DOSAGE FORMS AND STRENGTHS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Tablets: 10&nbsp;mg\u00d730 tablets<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>CONTRAINDICATIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Concomitant use with strong CYP3A4 inhibitors. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Patients with adrenal insufficiency.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>WARNINGS AND PRECAUTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Hyperkalemia. Patients with decreased kidney function and higher baseline potassium levels are at increased risk. &nbsp;Monitor serum potassium levels and adjust dose as needed.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>ADVERSE REACTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Adverse reactions occurring in \u2265 1% of patients on LUCIFINE and more frequently than placebo are hyperkalemia, hypotension, and hyponatremia. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DRUG INTERACTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Strong CYP3A4 Inhibitors: Use is contraindicated.<\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Grapefruit or grapefruit juice: Avoid concomitant use. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Moderate or weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either LUCIFINE or the moderate or weak CYP3A4 inhibitor, and adjust LUCIFINE dosage as appropriate.<\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Strong or moderate CYP3A4 Inducers: Avoid concomitant use.<\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>USE IN SPECIFIC POPULATIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Lactation: Breastfeeding not recommended.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>Storage <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Store at 20\u2103&nbsp;to 25\u2103&nbsp;(68\u2109&nbsp;to 77\u2109), excursions permitted between 15\u2103&nbsp;and 30\u2103&nbsp;(59\u2109&nbsp;and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;<\/span><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LUCIFINE is a non-steroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).<\/p>","protected":false},"featured_media":2097,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[34],"product_tag":[],"class_list":["post-250","product","type-product","status-publish","has-post-thumbnail","product_cat-kidney-disease","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product\/250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/comments?post=250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/media\/2097"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/media?parent=250"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product_brand?post=250"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product_cat?post=250"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/es\/wp-json\/wp\/v2\/product_tag?post=250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}